Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study.

Anne Hansen Ree,Hanne Hamre,Christian Kersten,Eva Hofsli,Marianne Grønlie Guren,Halfdan Sorbye,Christin Johansen,Anne Negård,Kjersti Flatmark,Sebastian Meltzer

Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study.

2021

Anne Hansen Ree
Hanne Hamre
Christian Kersten
Eva Hofsli
Marianne Grønlie Guren
Halfdan Sorbye
Christin Johansen
Anne Negård
Kjersti Flatmark
Sebastian Meltzer

3556Background: Immune checkpoint blockade (ICB) has revolutionized patient outcome for the small mCRC subgroup with highly immunogenic disease. The majority of mCRC cases, however, are MSS without...

Keywords:

Chemotherapy
Oncology
Nivolumab
Colorectal cancer
Internal medicine
Blockade
Oxaliplatin
Medicine
FLOX
Immune checkpoint
Disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations